Leprosy future or investigational therapies: Difference between revisions

Jump to navigation Jump to search
m (Changes made per Mahshid's request)
 
(11 intermediate revisions by 2 users not shown)
Line 4: Line 4:


==Overview==
==Overview==
 
Ongoing [[research]] focuses on the the mechanism of leprosy transmission as well as the identification of patients at high risk of infection in order to improve disease prevention and to treat infected individuals earlier. <ref name=WHO>{{cite web | title = Enhanced Global Strategy for Further Reducing the Disease Burden due to Leprosy | url = http://www.searo.who.int/entity/global_leprosy_programme/documents/enhanced_global_strategy_2011_2015_operational_guidelines.pdf }}</ref>  Identification of alternatives to existing [[drugs]], such as [[rifampicin]] is also critical in so far as these agents may be [[contraindicated]] either because of [[toxicity]] or [[resistance]]. <ref name=WHO>{{cite web | title = Enhanced Global Strategy for Further Reducing the Disease Burden due to Leprosy | url = http://www.searo.who.int/entity/global_leprosy_programme/documents/enhanced_global_strategy_2011_2015_operational_guidelines.pdf }}</ref>
==Future or investigational therapies==
Even though the [[incidence]] of leprosy has been decreasing throughout the last years, it should not decrease the research efforts to diminish the impact of this condition. It is important to find new, better and cost-effective ways to control the disease's incidence, particularly in endemic countries. For future research studies, major topics to keep in consideration are:
* Integration
* Quality
* Equity
* Sustainability
 
It is mandatory to identify the patterns of transmission of leprosy to better understand the factors influencing the not only the occurrence but also the transmission of the disease, in order to develop better mechanisms of prevention, treatment and management of individual patients, household contacts and populations in general.
 
Another priority for research is to develop better and more affordable approaches to identify the individuals in the population at higher risk of being infected, and to provide an early diagnosis of those already infected, in order to minimize the damages inflicted by leprosy in the quality of life of the individual.
 
In the case of the treatments already in place, it is important to find alternatives to provide, in case drugs like rifampicin are contraindicated, either because of toxicity or resistance to the drug, even though that might not be a present problem, it is a potential issue to would cause great damage in the future if no other drug was available.
 
As with all research studies, it is essential that results are communicated to the WHO and available worldwide in order to improve the current knowledge of prevention, management and treatment of leprosy patients and at the same time enhance further discoveries, that aim to eradicate leprosy on a worldwide basis.


==References==
==References==
Line 28: Line 14:
[[Category:Disease]]
[[Category:Disease]]
[[Category:Dermatology]]
[[Category:Dermatology]]
[[Category:Infectious disease]]
 
[[Category:Tropical disease]]
[[Category:Tropical disease]]
[[Category:Leprosy]]
[[Category:Leprosy]]
Line 34: Line 20:
[[Category:Bacterial diseases]]
[[Category:Bacterial diseases]]
[[Category:Neglected diseases]]
[[Category:Neglected diseases]]
[[Category:Needs content]]

Latest revision as of 18:10, 18 September 2017

Leprosy Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Leprosy from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Tertiary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Leprosy future or investigational therapies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Leprosy future or investigational therapies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Leprosy future or investigational therapies

CDC on Leprosy future or investigational therapies

Leprosy future or investigational therapies in the news

Blogs on Leprosy future or investigational therapies

Directions to Hospitals Treating Leprosy

Risk calculators and risk factors for Leprosy future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: João André Alves Silva, M.D. [2]

Overview

Ongoing research focuses on the the mechanism of leprosy transmission as well as the identification of patients at high risk of infection in order to improve disease prevention and to treat infected individuals earlier. [1] Identification of alternatives to existing drugs, such as rifampicin is also critical in so far as these agents may be contraindicated either because of toxicity or resistance. [1]

References

  1. 1.0 1.1 "Enhanced Global Strategy for Further Reducing the Disease Burden due to Leprosy" (PDF).


Template:WikiDoc Sources